RAIN — Rain Oncology Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Brief: Rain Oncology Inc Has No Exposure To Any Liquidity Concern At SVB
Rain Oncology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Rain Oncology Reports Fourth Quarter And Full Year 2022 Financial Results
Rain Oncology Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Adage Capital Partners, L.P. Reports 8.09% Passive Stake In Rain Oncology As Of January 20, 2023
Mizuho initiates coverage of Rain Oncology with 'buy', shares up
Piper Sandler sees Rain Therapeutics' lead cancer drug succeed in trial; ups PT
Brief: Rain Therapeutics Announces Name Change To Rain Oncology Inc
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Rain Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Rain Therapeutics Inc Reports Quarterly Loss Per Share Of $0.68
Rain Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview
Brief: Rain Therapeutics Announces $50 Million Registered Offering Of Common Stock
Brief: Rain Therapeutics Provides Interim Analysis Of Phase 2 Basket Trial Of Milademetan For MDM2-Amplified Advanced Solid Tumors
Brief: Rain Therapeutics Reports Second Quarter 2022 Financial Results
Brief: Rain Therapeutics Announces Completion Of Enrollment In Phase 3 Mantra Trial For Milademetan In Liposarcoma
Brief: Rain Therapeutics Announces Completion Of Enrollment In Phase 3 Mantra Trial For Milademetan In Liposarcoma
Rain Therapeutics jumps as Jones Research starts with 'buy'
U.S. RESEARCH ROUNDUP-Alexandria Real Estate Equities, Beacon Roofing Supply, Snowflake